Search our Database of Scientific Publications and Authors

I’m looking for a

    8906 results match your criteria Psoriatic Arthritis

    1 OF 179

    Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.
    J Rheumatol 2018 Jun 15. Epub 2018 Jun 15.
    From the Department of Medical Sciences, Policlinico of the University of Cagliari; Rheumatology Unit, and Department of Public Health, University of Cagliari, Cagliari; Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera; Rheumatology Research Unit, Department of Clinical and Experimental Medicine, University "Federico II," Naples; Department of Rheumatology, ASST Gaetano Pini-Centro Traumatologico Ortopedico (CTO), Milan; Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Modena and Reggio Emilia; Dipartimento di Medicina e Scienze della Salute, Università degli Studi del Molise, Campobasso, Italy; University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Academic Medical Center/University of Amsterdam; Amsterdam Rheumatology and Immunology Center Reade, Amsterdam, the Netherlands; Rehabilitation Teaching and Research Unit, Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand; Medizinische Klinik III mit Poliklinik, Friedrich-Alexander- Universität Erlangen-Nuernberg, Erlangen, Germany; Sector of Dermatology, HUCFF School of Medicine, Federal University of Rio de Janeiro and Sector of Dermatology, HUPE School of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil; Spondyloarthritis Program, Johns Hopkins University, School of Medicine, Baltimore, Maryland; Swedish Medical Centre and University of Washington School of Medicine, Seattle, Washington, USA; Department of Rheumatology, Semmelweis University, Budapest, Hungary; Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK. Funded by Regione Autonoma della Sardegna - L.R. n. 7/2007 annualità 2012, CRP-60098, linea A2, "Consorzio internazionale PEAC: meccanismi patogenetici nelle Spondiloartriti." A. Cauli, MD, PhD, Department of Medical Science, Policlinico di Monserrato, University of Cagliari; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program University Health Network; A. Mathieu, MD, Professor of Rheumatology and Head of Rheumatology Unit, University of Cagliari; G. Porru, MD, Department of Medical Science, Policlinico di Monserrato, University of Cagliari; P.P. Tak, MD, PhD, Professor of Rheumatology, Academic Medical Center/University of Amsterdam; C. Sardu, MD, Department of Public Health, University of Cagliari; R. Scarpa, MD, Professor of Rheumatology, Rheumatology Research Unit, Department of Clinical and Experimental Medicine, University "Federico II"; A. Marchesoni, MD, Department of Rheumatology, ASST Gaetano Pini-CTO; W.J. Taylor, PhD, MBChB, FRACP, FAFRM, Rehabilitation Teaching and Research Unit, and Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago; C. Salvarani, MD, Professor of Rheumatology, Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia; J. Kalden, MD, Medizinische Klinik III mit Poliklinik, Friedrich-Alexander-Universität Erlangen- Nuernberg; E. Lubrano, MD, PhD, Associate Professor of Rheumatology, Dipartimento di Medicina e Scienze della Salute, Università degli Studi del Molise; S. Carneiro, MD, PhD, Dermatologist and Rheumatologist, HUCFF Federal University of Rio de Janeiro, and Associate Professor of Dermatology, School of Medical Sciences, State University of Rio de Janeiro; M. Piga, MD, Department of Medical Science, Policlinico di Monserrato, University of Cagliari; A. Floris, MD, Rheumatology Unit, University of Cagliari; F. Desiati, MD, Department of Rheumatology, ASST Gaetano Pini-CTO; J.A. Flynn, MD, MBA, Med, Professor of Medicine, Director Spondyloarthritis Program, Johns Hopkins University, School of Medicine; S. D'Angelo, MD, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera Italy, and PhD Scholarship in Health Sciences, Department of Health Sciences, University of Molise; A.W. van Kuijk, MD, PhD, Amsterdam Rheumatology and Immunology Center Reade; M.G. Catanoso, MD, Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia; F. Caso, MD, PhD, Assistant Professor, Rheumatology Research Unit, Department of Clinical and Experimental Medicine, University "Federico II"; P. Contu, MD, Department of Public Health, University of Cagliari; I. Ujfalussy, MD, Department of Rheumatology Semmelweis University; P.S. Helliwell, MD, PhD, Leeds Institute of Molecular Medicine, University of Leeds; P.J. Mease, MD, Swedish Medical Center Rheumatology Research Division; Clinical Professor, University of Washington School of Medicine. Ignazio Olivieri, MD, died July 28, 2017; he was Director of the Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera. Address correspondence to Prof. A. Cauli, Dipartimento di Scienze Mediche, Università di Cagliari, ss 554, Monserrato 09042, Italy. E-mail: Accepted for publication February 28, 2018.
    Objective: Physician's global assessment (PGA) of disease activity is a major determinant of therapeutic decision making. This study assesses the reliability of the PGA, measured by means of 0-100 mm visual analog scale (VAS), and the additional use of separate VAS scales for musculoskeletal (PhysMSK) and dermatologic (PhysSk) manifestations in patients with psoriatic arthritis (PsA).

    Methods: Sixteen centers from 8 countries enrolled 319 consecutive patients with PsA. Read More

    Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
    BMJ Open 2018 Jun 14;8(6):e021082. Epub 2018 Jun 14.
    Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany.
    Objective: The Non Interventional Evaluation with Golumimab (GO-NICE) study aimed to document patient and treatment characteristics as well as clinical effectiveness and safety in adult patients newly treated with the tumour necrosis factor inhibitor golimumab (GLM).

    Design: Prospective non-interventional study with 24-month observation per patient.

    Setting: 158 office-based and clinical-based physicians in Germany. Read More

    Functional role of human interleukin-32 and nuclear transcription factor-kB in patients with psoriasis and psoriatic arthritis.
    Int J Health Sci (Qassim) 2018 May-Jun;12(3):29-34
    Department of Medical Biochemistry, College of Medicine, Qassim University, Buraidah, KSA.
    Objective: Inflammation and its associated cell signaling events have been well documented in psoriasis and psoriatic arthritis. However, the potential for interleukin (IL)-32 and its associated signaling to provoke an inflammatory response or to contribute in the pathogenesis of psoriasis or psoriatic arthritis are still in early phase. This study determined the role of IL-32 and nuclear transcription factor (NF)-κB in patients with plaque psoriasis and psoriatic arthritis. Read More

    Effect of anti-rheumatic treatment on selenium levels in inflammatory arthritis.
    J Trace Elem Med Biol 2018 Sep 3;49:91-97. Epub 2018 May 3.
    Lillehammer Hospital for Rheumatic Diseases, Norway; Department of Research, Innlandet Hospital Trust, Brumunddal, Norway; Harvard Medical School, Boston, USA; Brigham and Women's Hospital, Boston, USA.
    Objectives: The reason for increased cardiovascular risk in inflammatory arthritis (IA) is unclear. Interestingly, selenium-deficiency is suspected to contribute to the development of cardiovascular disease (CVD) in the general population. Although the reference range of serum selenium (s-selenium) is 50-120 μg/L, there are indications that levels up to 85 μg/L might not be sufficient for optimal cardioprotection. Read More

    Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers.
    Rheumatology (Oxford) 2018 Jun 9. Epub 2018 Jun 9.
    Rigshospitalet Gentofte, Center for Rheumatology and Spine Diseases.
    Objective: We aimed to investigate gender differences in disease manifestations, patient-reported outcomes, comorbidities and treatment effectiveness among patients with PsA treated with their first TNFα inhibitor (TNFI).

    Methods: In this observational cohort study, the DANBIO register provided prospectively collected data on PsA patients who initiated their first TNFI in 2000-15. Comorbidity information was achieved from the Danish Nationwide Patient Register. Read More

    Clinical management of psoriatic arthritis.
    Lancet 2018 Jun 1;391(10136):2285-2294. Epub 2018 Jun 1.
    Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
    Psoriatic arthritis, or the broader term psoriatic disease, refers to an inflammatory disorder that affects multiple organs, including the skin and joints, and that also has related extra-articular manifestations and can have comorbidities. Patients with psoriatic disease have a substantial clinical burden. Early identification leading to timely diagnosis and treatment is crucial to prevent long-term structural damage and disability and the associated socioeconomic consequences. Read More

    The pathogenesis of psoriatic arthritis.
    Lancet 2018 Jun 1;391(10136):2273-2284. Epub 2018 Jun 1.
    Rheumatology EULAR Centre of Excellence, St Vincent's University Hospital and University College Dublin, Dublin, Ireland; Department of Molecular Rheumatology, Trinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland.
    Psoriatic arthritis is a chronic, immune-mediated, inflammatory arthropathy that presents with inflammation of the joints and entheses, including those of the axial skeleton, and is associated with increased mortality from cardiovascular disease. Diagnosis is primarily based on clinical phenotype because of the diversity of the associated features, which can include skin and nail disease, dactylitis, uveitis, and osteitis. Improved understanding of the pathogenesis of psoriatic arthritis has led to the development of effective biologics and small-molecular drugs targeting specific cytokines and signalling pathways, which can prevent disease progression and improve quality of life. Read More

    Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Lancet 2018 Jun 1;391(10136):2213-2224. Epub 2018 Jun 1.
    Immunology, Janssen Research & Development, Spring House, PA, USA.
    Background: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. Read More

    Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals.
    Actas Dermosifiliogr 2018 Jun 8. Epub 2018 Jun 8.
    Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, España.
    Background: There is currently little information available on the management of patients with psoriasis in the daily clinical practice of dermatologists in Spain.

    Objective: The aim of this study was to survey a group of Spanish dermatologists with particular expertise in the management of psoriasis to determine their opinions on the protocols used in routine clinical practice.

    Material And Methods: A cross-sectional study based on an online survey about the management of psoriasis sent to 75 dermatologists. Read More

    Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.
    Curr Opin Rheumatol 2018 Jun 9. Epub 2018 Jun 9.
    Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK.
    Purpose Of Review: The spondyloarthopathies (SpA), which encompass related diseases that were originally viewed as autoimmune, are now known to have a strong innate immune or autoinflammatory initiation phase characterized by disease localization to tissue-specific sites based on the nuances and microanatomy and immunology of those sites. This review covers recent translational advances in the field of SpA.

    Recent Findings: Imaging studies in SpA continue to add support for the pivotal role of enthesitis in disease initiation and expression. Read More

    Impact of obesity on autoimmune arthritis and its cardiovascular complications.
    Autoimmun Rev 2018 Jun 6. Epub 2018 Jun 6.
    Jesse Brown VA Medical Center, Chicago, IL 60612, United States; Department of Medicine, Division of Rheumatology, University of Illinois at Chicago, IL 60612, United States. Electronic address:
    Obesity can instigate and sustain a systemic low-grade inflammatory environment that can amplify autoimmune disorders and their associated comorbidities. Metabolic changes and inflammatory factors produced by the adipose tissue have been reported to aggravate autoimmunity and predispose the patient to cardiovascular disease (CVD) and metabolic comorbidities. Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are autoimmune arthritic diseases, often linked with altered body mass index (BMI). Read More

    [Methods of efficacy assessment of the knee joint radiosynoviorthesis- personal experience].
    Wiad Lek 2018 ;71(1 pt 1):10-16
    Katedra i Klinika Reumatologii i Układowych Chorób Tkanki Łącznej, Uniwersytet Medyczny, Lublin, Polska.
    Objective: Introduction: Radiosynoviorthesis (RS) is local method of treatment of remittent joint effusions among patients who obtained general improvement after disease modifying anti-rheumatic drugs therapy but one or a few joints stay resistant to this treatment and intraarticular corticosteroids injections. The aim: The attempt to identification methods of efficacy assessment of the 90yttrium knee joint RS.

    Patients And Methods: Material and methods: The study group consisted of 43 patients with rheumatoid arthritis (RA) and 19 patients with inflammatory spondyloarthropaties (SPA) where 8 patients were treated for ankylosing spondylitis (AS), 4 for psoriatic arthritis (PsA) and 7 due to undifferentiated inflammatory spondyloarthropaties (USPA). Read More

    The impact of high intensity interval training on disease activity and patient disease perception in patients with psoriatic arthritis: A randomized controlled trial.
    Arthritis Care Res (Hoboken) 2018 Jun 8. Epub 2018 Jun 8.
    Dept. of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
    Objective: The aim of this study was to evaluate the impact of high intensity interval training (HIIT) on disease activity and patient disease perception in patients with psoriatic arthritis (PsA), and evaluating if a potential effect could be sustained for a longer period.

    Methods: We randomly assigned 67 PsA patients (43 women and 24 men) to an intervention group performing HIIT for 11 weeks or a control group who were instructed to not change their physical exercise habits. Outcomes were assessed at three and nine months with the patient global assessment (PGA), fatigue, and pain measured on a 100 mm visual analog scale and the composite disease activity score of 44 joints (DAS44) was calculated. Read More

    Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis.
    Arthritis Res Ther 2018 Jun 7;20(1):114. Epub 2018 Jun 7.
    Departamento de Medicina Interna, Facultad de Medicina, Universidad de La Laguna, La Laguna, Tenerife, Spain.
    Background: B cells exert their pathogenic action in rheumatoid arthritis (RA) locally in the synovium. This study was undertaken to elucidate the chemokines responsible for the recruitment of B cells in the inflamed synovium, taking into account that the rich chemokine milieu present in the synovial tissue can fine-tune modulate discrete chemokine receptors.

    Methods: Expression levels of chemokine receptors from the CC and CXC family, as well as CD27, were assessed by flow cytometry in CD20 mononuclear cells isolated from the peripheral blood (PB) and synovial fluid (SF) of RA and psoriatic arthritis patients. Read More

    Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    Arthritis Res Ther 2018 Jun 7;20(1):113. Epub 2018 Jun 7.
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
    Background: Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including HRQoL, among patients with active PsA. This analysis evaluates the effect of secukinumab on patient-reported pain in PsA through 104 weeks of treatment. Read More

    Building a Citizen Pscientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts.
    Dermatol Ther (Heidelb) 2018 Jun 6. Epub 2018 Jun 6.
    Department of Dermatology, University of California San Francisco, San Francisco, USA.
    Introduction: To design and implement a novel cloud-based digital platform that allows psoriatic patients and researchers to engage in the research process.

    Methods: Citizen Pscientist (CP) was created by the National Psoriasis Foundation (NPF) to support and educate the global psoriatic disease community, where patients and researchers have the ability to analyze data. Psoriatic patients were invited to enroll in CP and contribute health data to a cloud database by responding to a 59-question online survey. Read More

    Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls.
    Ann Rheum Dis 2018 Jun 6. Epub 2018 Jun 6.
    Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
    Objectives: To compare (1) Short Form-36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS), scale scores and Short Form-6 dimensions (SF-6D) between patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) and Norwegian general population controls and (2) improvements in these measures between patients with RA and PsA.

    Methods: Analyses of covariance were performed to compare SF-36 measures between first-time enrolled patients with RA (n=3898) and PsA (n=1515) from the prospective observational multicentre NORwegian-Disease Modifying Anti-Rheumatic Drug study (6 months follow-up) and general population controls (n=2323).

    Results: In age and gender-adjusted analyses, patients with PsA compared with patients with RA had similar PCS, MCS and SF-6D (p≥0. Read More

    Current Status and Future Prospects of Small-Molecule Protein-Protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).
    Curr Top Med Chem 2018 Jun 6. Epub 2018 Jun 6.
    NovaMechanics Ltd, Nicosia. Cyprus.
    The overexpression of Tumor Necrosis Factor (TNF) is directly related to the development of several autoimmune diseases, such as rheumatoid and psoriatic arthritis, inflammatory bowel disease, Crohn's disease, refractory asthma, and multiple sclerosis. Receptor activator of nuclear factor kappa-B ligand (RANKL) belongs to the TNF family, and is the primary mediator of osteoclast-induced bone resorption through interaction with its receptor RANK. The function of RANKL is physiologically inhibited by the action of osteoprotegerin (OPG), which is a decoy receptor that binds to RANKL and prevents the process of osteoclastogenesis. Read More

    Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.
    JAMA Dermatol 2018 Jun 6. Epub 2018 Jun 6.
    Department of Dermatology, Keck School of Medicine of University of Southern California, Los Angeles.
    Importance: There is no consensus on which domains should be measured or which instruments should be used in clinical trials for psoriasis therapies.

    Objective: To achieve international consensus among psoriasis stakeholders on a core set of domains that should be measured in all psoriasis clinical trials.

    Design, Setting, And Participants: Literature review, pre-Delphi survey exercises, nominal group discussions, and audience voting at 4 stakeholder meetings were used to develop candidate domains for 2 rounds of a Delphi survey. Read More

    IL-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses.
    Arthritis Rheumatol 2018 Jun 5. Epub 2018 Jun 5.
    Departmentof Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, The Netherlands.
    Objective: Secukinumab(anti-IL-17A) is an effective therapy for ankylosing spondylitis(AS) and psoriatic arthritis(PsA), the prototypical forms of spondyloarthritis(SpA). This study assessed if secukinumab modulates the immunopathology of target lesions without blunting systemic immune responses, using peripheral SpA(pSpA) as model.

    Methods: 20 active peripheral SpA patients were included in a 12 week open-label trial with secukinumab (300mg weekly for 4 weeks followed every 4 weeks). Read More

    Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Aliment Pharmacol Ther 2018 Jun 5. Epub 2018 Jun 5.
    Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
    Background: There are increasing reports of paradoxical psoriasiform diseases secondary to anti-tumour necrosis factor (TNF) agents.

    Aims: To determine the risks of paradoxical psoriasiform diseases secondary to anti-TNF agents in patients with inflammatory bowel disease (IBD).

    Methods: A nationwide population study was performed using the Korea National Health Insurance Claim Data. Read More

    Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis.
    Clin Rheumatol 2018 Jun 4. Epub 2018 Jun 4.
    AbbVie Inc., North Chicago, IL, USA.
    To compare disease burden and biologic use among psoriatic arthritis (PsA) or rheumatoid arthritis (RA) patients recruited to the Corrona registry. Retrospective study of patients with PsA or RA enrolled in Corrona between January 2002 and March 2013 and grouped in 2-year intervals. Clinical outcomes and biologic use were assessed. Read More

    Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus.
    Front Immunol 2018 7;9:989. Epub 2018 May 7.
    Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
    Deficient clearance of apoptotic cells reportedly contributes to the etiopathogenesis of the autoimmune disease systemic lupus erythematosus (SLE). Based on this knowledge, we developed a highly specific and sensitive test for the detection of SLE autoantibodies (AAb) utilizing secondary NEcrotic cell (SNEC)-derived material as a substrate. The goal of the present study was to validate the use of SNEC as an appropriate antigen for the diagnosis of SLE in large cohort of patients. Read More

    Psoriasis and Psoriatic Spectrum Disease: A Primer for the Primary Care Physician.
    Am J Med 2018 Jun 1. Epub 2018 Jun 1.
    Complex Medical Dermatology Clinic, St. Elizabeth Physicians, Florence, KY.
    Psoriasis is a chronic, immune-mediated disorder that affects approximately 7.5 million people in the United States. Individuals with psoriasis may develop cutaneous, articular, and systemic manifestations, which are a source of significant morbidity, heighted risk of mortality. Read More

    Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study.
    RMD Open 2018 21;4(1):e000668. Epub 2018 May 21.
    Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
    Objectives: Imaging studies in patients with cutaneous psoriasis have demonstrated asymptomatic bone and tendon changes, commonly of the foot and ankle. We sought to determine if patients with cutaneous psoriasis have an increased risk of clinically significant foot and ankle tendinopathy or enthesopathy compared with the general population.

    Methods: Patients with cutaneous psoriasis and a general population cohort were identified in The Health Improvement Network, a general practice medical records database from the UK. Read More

    Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
    Rheumatol Ther 2018 Jun 1. Epub 2018 Jun 1.
    Novartis Pharma AG, Basel, Switzerland.
    Under Methods section, heading Analyses: Pairwise Comparisons, one of the probability value was published incorrectly in a sentence. The correct sentence should read as follows. Read More

    Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype.
    Rheumatol Ther 2018 Jun 1. Epub 2018 Jun 1.
    ASST Gaetano Pini-CTO, Milan, Italy.
    Details continue to emerge on psoriatic arthritis, expanding our understanding of its pathogenesis and clinical features. This has led to the evolution of management guidelines, which now recognize additional disease manifestations. In this rapidly changing area, it is timely to review the latest evidence and discuss whether management strategies are meeting patients' needs. Read More

    Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.
    J Rheumatol Suppl 2018 Jun;94:54-61
    From the Rheumatology Research Unit, Cambridge University Hospitals UK National Health Service (NHS) Foundation Trust, Cambridge; University of Leeds, Leeds; Bradford Hospitals NHS Foundation Trust, Bradford, UK; Department of Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Krembil Research Institute, Toronto, Ontario, Canada; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Southern California, Los Angeles, California; University of Utah, Salt Lake City, Utah; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Our Lady's Hospice and Care Services; Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Department of Medical Humanities, VU University Medical Centre, Amsterdam, the Netherlands.
    The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Collaborative Research Network (CRN) is an endeavor that aims to address gaps in the knowledge of the etiopathogenesis and management of psoriatic disease by best using the large community of experienced investigators who are already collecting rich clinical phenotype data and biologic samples using validated techniques. Exemplar rheumatology and dermatology projects will inform strategies to implement the CRN, while input and funding from government organizations, charities, and industry will shape the CRN. The key immediate priorities to establish the CRN are discussed herein and include (1) strategies for building infrastructure to collect and store biosamples and associated clinical data, (2) best practices for sample collection and storage, (3) approaches to engage the GRAPPA community of investigators and industry to collaborate most effectively on shared priorities, and (4) agreement on a funding strategy. Read More

    The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting.
    J Rheumatol Suppl 2018 Jun;94:52-53
    From the Advisory Services, IQVIA, Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina; International Dermatology Outcome Measurers, Windsor, Connecticut; Johns Hopkins University School of Medicine, Center for Child and Community Health Research, Baltimore, Maryland; Cleveland Clinic, Cleveland, Ohio, USA; Our Lady's Hospice and Care Services, Dublin, Ireland; Department of Medical Humanities, VU University Medical Centre, Amsterdam, the Netherlands; Biomedical Laboratory Scientist, Oslo University Hospital, Oslo, Norway; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; Toronto Western Hospital, Psoriatic Arthritis Clinic, Toronto, Ontario, Canada.
    The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has reached the third of 5 stages of organizational maturity regarding incorporating patient research partners (PRP) into psoriatic arthritis (PsA) and psoriasis research and educational efforts. Herein, we report the involvement of PRP at the GRAPPA 2017 annual meeting and plans for future PRP engagement. Read More

    GRAPPA 2017 Project Report.
    J Rheumatol Suppl 2018 Jun;94:48-51
    From the University of Utah, Salt Lake City, Utah; University of California at San Diego, La Jolla, California; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; New York University School of Medicine, New York; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
    At the 2017 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members received updates on several ongoing educational and research efforts. Among them were updates on GRAPPA's continued education efforts; GRAPPA's continued research efforts, including the Biomarker Project, a collaborative research effort to identify and study biomarkers of joint damage; treatment recommendations, including recommendations and core principles related to biosimilars; efforts to update GRAPPA's Website and to create a GRAPPA smart-phone application (app); and the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network. Read More

    Options for Assessing Joints and Entheses in Psoriatic Arthritis by Ultrasonography and Magnetic Resonance Imaging: How to Move Forward.
    J Rheumatol Suppl 2018 Jun;94:44-47
    From the University of Toronto and Women's College Hospital, Toronto; University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario; University of Alberta, Edmonton, Alberta, Canada; University of Florida College of Medicine, Jacksonville, Florida, USA; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
    Psoriatic arthritis (PsA) is a heterogeneous disease with various manifestations of musculoskeletal inflammation. Recent advances in imaging, including ultrasound (US) and magnetic resonance imaging (MRI), allow for the accurate evaluation of the extent of inflammation and damage in the peripheral joints, spine, and entheses. The development and validation of outcome measures are critical steps in creating standardized evaluations of musculoskeletal inflammation and damage in psoriatic patients. Read More

    Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting.
    J Rheumatol Suppl 2018 Jun;94:40-43
    From the Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, New York; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology and Immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands.
    At the 2017 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the International Dermatology Outcome Measures (IDEOM) psoriasis working group presented an overview of its cutaneous domain of psoriatic arthritis (PsA) projects. First, the group presented an overview of IDEOM's work to establish psoriasis outcome measures that satisfy the needs of all those involved. Second, the group discussed replacements for the Psoriasis Area and Severity Index (PASI) that can be used in clinical practice, including data that support the use of the physician's global assessment × body surface area measurement score as a PASI surrogate. Read More

    The Role of the Microbiome in Gut and Joint Inflammation in Psoriatic Arthritis and Spondyloarthritis.
    J Rheumatol Suppl 2018 Jun;94:36-39
    From the Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, University Hospital Ghent; the Vlaams Instituut voor Biotechnologie (VIB) Center for Inflammation Research (IRC), Ghent, Belgium.
    Spondyloarthritis (SpA) encompasses a group of diseases characterized by an inflammatory arthritis involving both joints and entheses. However, extraarticular symptoms constitute a large element of the pathology and should not be underestimated. Microscopic gut inflammation is observed in 50% of patients with SpA and has been linked to disease activity, underscoring the effect of gut inflammation in SpA. Read More

    The Microbiome in Psoriasis and Psoriatic Arthritis: Joints.
    J Rheumatol Suppl 2018 Jun;94:32-35
    From the Psoriatic Arthritis Center, Division of Rheumatology, New York University Langone Health; Microbiome Center for Rheumatology and Autoimmunity (MiCRA), Division of Rheumatology, New York University School of Medicine and Hospital for Joint Diseases, New York, New York, USA.
    The microbiome is a known and established immunomodulator of many inflammatory disorders, including psoriasis and psoriatic arthritis. Microbes co-evolved with their human hosts and provide them with nutritional, metabolic, and immunologic support. An accumulating body of evidence has revealed that psoriatic diseases are characterized by a state of intestinal dysbiosis, which has been linked to a decrease in beneficial commensals and fatty acids. Read More

    The Microbiome in Psoriasis and Psoriatic Arthritis: The Skin Perspective.
    J Rheumatol Suppl 2018 Jun;94:30-31
    From the Department of Dermatology, Erasmus University Medical Centre, Rotterdam, the Netherlands.
    Psoriasis is a chronic, inflammatory immune-mediated skin disease that affects about 2% of the world's population. In 20% of patients with psoriasis, the characteristic skin lesions are accompanied by psoriatic arthritis (PsA). Psoriasis arises in genetically predisposed individuals who have a dysregulated immune response to various environmental factors. Read More

    The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.
    J Rheumatol Suppl 2018 Jun;94:26-29
    From the University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Orthopedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford; Department of Rheumatology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Royal National Hospital for Rheumatic Diseases; University of Bath, Bath, UK; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Department of Rheumatology, Erasmus Medical Center, Rotterdam, the Netherlands.
    The members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have shown great interest in developing a common GRAPPA database. To address this interest, GRAPPA included a symposium at its 2017 annual meeting to examine the concepts of registries and databases. At this symposium, examples of existing databases were reviewed, and their challenges and achievements were discussed. Read More

    Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.
    J Rheumatol Suppl 2018 Jun;94:17-25
    From the Royal Prince Alfred Hospital Medical Centre, Sydney, Australia; Royal National Hospital for Rheumatic Diseases, Bath, UK; University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; University of Toronto, Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Oxford, Oxford, UK; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA; Department of Rheumatology, St. Vincents University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; VU Medical Centre, Amsterdam, the Netherlands; IQVIA, Duke University School of Medicine, Durham, North Carolina, USA; School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
    The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Read More

    Juvenile Psoriatic Arthritis: A Report from the GRAPPA 2017 Annual Meeting.
    J Rheumatol Suppl 2018 Jun;94:11-16
    From the Department of Rheumatology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; Department of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University, Stanford, California, USA.
    Juvenile psoriatic arthritis (JPsA), a subtype of juvenile idiopathic arthritis (JIA), constitutes 5% of JIA. The literature is inconsistent regarding features of JPsA, and physicians debate whether it is a distinct entity within JIA. A biphasic age of onset distribution has been noted. Read More

    GRAPPA Trainees Symposium 2017: A Report from the GRAPPA 2017 Annual Meeting.
    J Rheumatol Suppl 2018 Jun;94:4-10
    From the Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Department of Dermatology, Division of Dermatology and Venereology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
    At the 2017 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Amsterdam, the Netherlands, a trainees symposium was held. Rheumatology and dermatology trainees engaged in psoriasis or psoriatic arthritis research presented their work. This report briefly reviews 6 oral presentations and 25 posters presented at the meeting. Read More

    Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
    J Rheumatol Suppl 2018 Jun;94:1-3
    From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; GRAPPA, Seattle, Washington; New York Medical College, Metropolitan Hospital, New York, New York, USA.
    The 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Amsterdam, the Netherlands, and was attended by rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patients. As in previous years, GRAPPA members held a symposium for trainees to discuss their research in psoriatic disease with experts in the field. Other subjects featured during the annual meeting included a discussion of the history, clinical features, controversies, and immunogenetics of juvenile psoriatic arthritis; updates from working groups in Outcome Measures in Rheumatology and International Dermatology Outcome Measures; a discussion of the benefits and challenges of setting up a longitudinal psoriatic arthritis (PsA) database; 3 separate discussions of the effects of the microbiome on skin and joints in psoriasis and PsA; a discussion of options for assessing joints and entheses in PsA by ultrasonography and magnetic resonance imaging; an update on GRAPPA's research and educational projects; a discussion of patient centricity, including the incorporation of patient research partners (PRP) into psoriasis and PsA research and educational efforts, from GRAPPA's PRP; and a discussion of the GRAPPA-Collaborative Research Network's inaugural meeting. Read More

    Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response.
    Arthritis Rheumatol 2018 May 31. Epub 2018 May 31.
    AbbVie Inc, North Chicago, IL.
    Objective: This study investigated the safety and efficacy of ABT-122, a TNF- and IL-17A-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) with an inadequate response to methotrexate.

    Methods: Patients (N=240) were randomized to receive ABT-122 (120 or 240 mg every week), adalimumab (40 mg every other week), or placebo in a 12-week, double-blind, parallel-group study (NCT02349451). The primary efficacy endpoint was ≥20% improvement in American College of Rheumatology criteria (ACR20 response) at week 12. Read More

    Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Inflamm Bowel Dis 2018 May 30. Epub 2018 May 30.
    Pfizer Inc., Collegeville, Pennsylvania.
    Background: Tofacitinib is an oral, small molecule Janus kinase inhibitor that is being investigated for ulcerative colitis (UC). Tofacitinib is approved for rheumatoid arthritis and psoriatic arthritis, where it has been shown to increase herpes zoster (HZ) risk. We evaluated HZ risk among UC patients using tofacitinib. Read More


    MicroRNA Expression Profiling in Psoriatic Arthritis.
    Biomed Res Int 2018 23;2018:7305380. Epub 2018 Apr 23.
    Department of Medicine, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy.
    Background: Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by bone erosions and new bone formation. MicroRNAs (miRNAs) are key regulators of the immune responses. Differential expression of miRNAs has been reported in several inflammatory autoimmune diseases; however, their role in PsA is not fully elucidated. Read More

    Influence of and Gene Polymorphisms on the Spondyloarthritis Immunopathogenesis, Regardless of HLA-B27, in a Brazilian Population.
    Mediators Inflamm 2018 19;2018:1395823. Epub 2018 Apr 19.
    Post Graduation Program of Biosciences and Physiopathology, Department of Analysis Clinical and Biomedicine, Maringa State University, Maringá, PR, Brazil.
    Background And Objectives: Spondyloarthritis (SpA) represents a heterogeneous group of immune-mediated inflammatory diseases that have overlapping clinical features, genetic predisposition, and pathogenic mechanisms. Hence, we investigated, through a case-control study, whether single-nucleotide polymorphisms of and genes are associated with SpA, ankylosing spondylitis (AS), and psoriatic arthritis (PsA) in a mixed Brazilian population.

    Methods: Genotyping of -308 (rs1800629), -238 (rs361525), (rs2275913), (rs763780), and polymorphisms was performed in 243 patients with SpA and 210 controls from Southern Brazil using SSOP-Luminex (One Lambda) and PCR-SSP assays. Read More

    1 OF 179